Getinge will gradually phase out its surgical perfusion business, to focus on more profitable growth areas such as ECLS and ...
CEO Mattias Perjos said surgical perfusion has “been a struggling category” since an FDA consent decree forced Getinge off the U.S. market in 2015.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback